Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapid Release Gels, Arthritis Formulation Put Tylenol In US OTC Analgesic Lead

Executive Summary

Tylenol brand consumption grows 10% on sales of Rapid Release Gel and Tylenol Arthritis, reaching top spot among analgesic products in the US, J&J says. Retailers' inventory builds as a result of prior-year supply constraints driven by Hurricane Maria also helped drive growth.

You may also be interested in...



J&J Launches Neutrogena Bright Boost, Children's Tylenol Dissolve Packs

Neutrogena Bright Boost line launches with technology borrowed from J&J's recently acquired NeoStrata high-end skin care line, worldwide consumer health chief Thibaut Mongon says. J&J also launches Children’s Tylenol Dissolve Packs.

J&J Relaunches Johnson’s Baby Care As Greener, Gentler, With Fewer Ingredients

The overhaul in line with “modern parents’ preferences” could be what’s needed to rouse the sleepy brand and spur Consumer business growth.

Adding Zarbee's, J&J Gains Natural Market Footprint, Claims Credibility

Zarbee's Naturals vitamin, mineral and dietary supplement products were launched in 2008 by a physician interested in offering non-drug alternative remedies for children and adults for indications such as cough and cold, sore throat, immune support, sleep and digestive health. J&J on the other hand, has been challenged in class action litigation about natural claims it's used on some of its Aveeno and Neutgrogena skin care product labels.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148730

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel